Baxter International Inc.

Baxter Healthcare Sa

University of Pittsburgh

Stemnion, Inc.

Epic Therapeutics, Inc.

Noveome Biotherapeutics, Inc.

Other

Alkermes Controlled Therapeutics, Inc.

Enzytech, Ltd.

Purepac, Inc.

Transderm Technologies LLC

Seeleaf Inc.

Baxalta Gmbh

Larry R. Brown

Michael S. Healy

Larry Richard Brown

Terrence L Scott

Debra Lafreniere

Vered Bisker-Leib

Nick Giannoukakis

Charles D Blizzard

George L Sing

James E Woiszwillo

John K McGeehan

Massimo M Trucco

Kimberly A Gillis

Howard C Wessel

Frank J Riske

Jie Di

Julia E Rashba-Step

Judith Sudhalter

Ton That Hai

Paul Jeffrey Sanders

Cong Jiang

Arounaguiry Ambroise

Michael S Healy

Guohan Yang

Bennett Melnick

Ed O'Connell

Catherine Quinn

Jie Li

Jennifer Machen

Wayne R Gombotz

Elazer Reuven Edelman

Uri Piran

Robert David Feeney

Linda O Palladino

Richard A Banas

Henry E Auer

Mark X Yang

John F Cline

Tyler A Okel

David Tseng

James Davidson, Deceased

Michael V Gallo

Eugene Mehr

Nick Giannoukakls

Elise M Gill

Wayne Gombotz

Terence L Scott

The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as 'CFS' compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

Treatment of systemic inflammatory responses

The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as 'CFS' compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as 'SR-CFS' compositions).

Treatment of diseases and conditions caused by increased vascular permeability

This present invention provides a delivery device that could be used to delivery discreet small volume of expensive biotechnology treatments to specific areas of the oral cavity, or other tissues. The present invention also provides a method of using the device disclosed herein to deliver biotechnology treatments and/or therapeutic agents to specific areas of the oral cavity, or other tissues. In one embodiment, the treatments and/or therapeutic agents are delivered to the interproximal area between and around the teeth.

Interproximal drug delivery device

A method, an article and a kit for the detection and visual indication of contact with or exposure to a polyhydroxyaromatic skin irritant found in the sap of a plant is provided herein. The article incorporates a colorless leuco dye that undergoes an instantaneous visible color change when contacted with or exposed to a polyhydroxyaromatic skin irritant in the sap of a plant or on a subject. This color change is an indication that contact with or exposure to a polyhydroxyaromatic skin irritant has occurred. Polyhydroxyaromatic skin irritants found in the sap of plants include those found in poison ivy, poison oak, poison sumac, poison dogwood, mango tree, cashew tree and lacquer tree. The leuco dye of the invention is Pergascript Red I-6B (1(3H)-isobenzofuranone,3,3-bis(2-methyl-1-octyl-1H-indol-3-yl)-).

Methods and articles for the detection of exposure to polyhydroxyaromatic skin irritants

The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as CFS compositions), such CFS compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ECS cells), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) obtained from culturing Amnion-derived Multipotent Progenitor (AMP) cells, dispersed in a polymeric coating material.

Medical device

The invention is directed to methods for treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve. The invention is further directed to treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve by administering to a subject suffering from such conditions Amnion-derived Cellular Cytokine Solution (ACCS), including immediate-release, targeted-release, and sustained-release (SR) ACCS compositions (referred to herein as 'SR-ACCS' compositions) and/or Amnion-derived Multipotent Progenitor (AMP) cell compositions. Such administration includes intranasal administration of ACCS and/or AMP cells.

Methods for treating ocular contusion and blunt injury and traumatic injury to the optic nerve

The invention is directed to methods for treating urushiol-induced contact dermatitis. Specifically, the invention is directed to treating and reducing inflammation associated with poison ivy, poison sumac and poison oak by administering to a subject suffering from such conditions novel cellular factor-containing solution compositions (referred to herein as 'CFS' compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as 'SR-CFS' compositions).

Methods for treating urushiol-induced contact dermatitis

Nucleic acids are prepared by dissolving compounds containing them in a suitable solvent or solvent system and forming microspheres from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nucleic acids is useful, such as in treatment of autoimmune disease.

Nucleic acid microspheres, production and delivery thereof

AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.

Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes

The present invention relates to polymeric derivatives, which can be conjugated to an amino-containing drug to improve its in vivo properties. The polymeric derivative can subsequently be released to yield the drug in its native form. Methods of preparing and using these polymeric derivatives and drug conjugates are described.

Polymeric benzyl carbonate-derivatives

The present disclosure is related to microparticle compositions, in which the microparticles are made of nucleic acids and non-polymeric cations, which are suitable for administration to moist or aqueous target locations (e.g., the lung tissue), where the substantially spherical nucleic acid microparticles release the nucleic acids through dissolution, allowing the released nucleic acids to freely interact with the target cells.

Nucleic acid microparticles for pulmonary delivery

The present disclosure relates to compositions of methods of making and compositions small compositions of particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in a single liquid phase. The solution is subjected to a liquid-solid phase separation to cause the active agent to form small spherical particles that are substantially amorphous or non-crystalline and are injectable through fine bore needles at high concentrations. The particles exhibit the pharmacokinetic and pharmacodynamnic properties of the active agent. The disclosure has special application for higher molecular weight proteins such as antibodies.

Protein microspheres retaining pharmacokinetic and pharmacodynamic properties

AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.

Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes

Growing community of inventors

Newton, MA, United States of America

Larry Richard Brown